EMD Serono aspires to create, improve and prolong life for people living with difficult-to-treat conditions like multiple sclerosis, cancer and infertility. Our people are courageous about advancing new science and passionate about delivering programs that make an impact on our communities.
We’re imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. Our strong pipeline explores potential new medicines across oncology, immuno-oncology and immunology, with the goal of combating a wide range of cancers, multiple sclerosis and other immunologic conditions.
Founded in 1992 in Germany, MorphoSys is dedicated to making innovative biopharmaceuticals to help patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development.
MorphoSys is headquartered in Planegg, Germany. In 2019, the US head office was established in Boston.
Epizyme, Inc. is a fully integrated biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through transformative epigenetic medicines. In addition to a robust research and discovery pipeline, Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them. For more information, visit www.epizyme.com.